Home / Reports

Reports

Barriers to biosimilars access in the US

The US Food and Drug Administration (FDA) has approved 26 biosimilars [1], yet only two are available on the market. A recent exploration [2] of this issue highlights the major obstacles to biosimilar access in the US.

GBMA publishes quarterly review of biosimilar literature

The Generic and Biosimilar Medicines Association (GBMA), which is the representative body of generic and biosimilar medicine suppliers in Australia, has released its quarterly review of biosimilar literature [1].

Biosimilars could have saved US companies US$1.4 billion in 2018

Increasing the use of biosimilar could have saved self-insured companies in the US up to US$1.4 billion on just two biologicals – infliximab and filgrastim – during 2018.

Market for copy biologicals in ASEAN and China expected to grow

The Association of Southeast Asian Nations (ASEAN) and China market for copy biologicals was valued at US687.6 million in 2017 and is expected to reach US$5.5 billion by 2025 with a compound annual growth rate (CAGR) of 29.7%, according to a new report by Allied Market Research.

Use of biosimilars for chronic inflammatory diseases in Canada

The high cost of originator biologicals in Canada has created a demand for biosimilars as a way of reining in costs for Canadian public healthcare payers. However, although several biosimilars are now commercially available in the country for a variety of conditions [1]; it has been suggested that the uptake of biosimilars in Canada remains low [2].

Advantages and challenges of biosimilars approved in Europe and the US

Each biosimilar has its own unique challenges on the market. At the 2019 Generic + Biosimilar Medicines Conference, Dr Amy Gutierrez, Chief Pharmacy Officer of not-for-profit healthcare plan Kaiser Permanente outlined these factors for four blockbuster drugs: bevacizumab, filgrastim, rituximab and trastuzumab [1].

Proposed policies to maximize societal benefit of biosimilars

During the European Commission’s (EC) fifth workshop on biosimilars, which was held in Brussels, Belgium on 30 October 2019, the subject of what policies might maximize the benefit of biosimilars to societies across Europe was discussed [1].

Optimizing the benefits of biosimilars for society

How to optimize the benefits of biosimilars for society was a topic discussed during the European Commission’s (EC) fifth workshop on biosimilars, which was held in Brussels, Belgium on 30 October 2019 [1].

Japanese opportunity for biosimilars

Japan is proving to be a favourable market for biosimilars, with more than half a billion dollars worth in sales waiting for prospective makers of biosimilars.

Brand-name discount cards increase private insurance spending in Canada

The use of brand-name discount cards, designed to help patients save money, increase private insurance expenditure by almost 50%, finds a study published in the Canadian Medical Association Journal [1].